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Pulmonary hypertension is a rare vascular disease that can affect patients with or surviving malignancy resulting in 
significant morbidity and high mortality. Malignant diseases can lead to elevated pulmonary artery pressure through 
different mechanisms, either directly by structural obstruction of pulmonary vessels or indirectly through hyperco-
agulable state or treatment toxicity culminating in high pulmonary vascular resistance. The most common causes of 
cancer-related pulmonary hypertension are thromboembolic diseases, tumour emboli and treatment toxicity and 
less commonly intravascular tumours and malignant extrinsic compression.
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Introduction
In recent years, advances in diagnosis and management 
strategies have improved the long-term survival of cancer 
patients, and about 60% of patients can now live for five 
years or more after diagnosis of malignancy [1]. The growing 
population of cancer-survived patients have a substantial 
risk of developing cardiovascular diseases due to ageing, 
co-morbid CV risk factors and cancer-specific adverse effects 
related to the malignancy itself or treatment toxicity [2]. 
Cardiovascular diseases have a significant impact on the 
quality of life and prognosis of cancer-survived patients 
and are considered the major non-malignant cause of mor-
tality [3–5]. The incidence of CV complications is difficult 
to estimate precisely due to variability in definitions, the 
presence of comorbid diseases affecting CV system and data 
collection stems mainly from registries and case series. The 
main manifestations of CVD are cardiomyopathy, coronary 
artery diseases, thromboembolic events, hypertension, ar-
rhythmias, pericardial diseases, valvular heart diseases and 
vascular diseases [6–8]. Pulmonary hypertension is a rare 
vascular disease that can affect patients with or surviving 
malignancy resulting in significant morbidity and high mor-
tality. In this review, we will explore the different etiologies 
and risk factors of pulmonary hypertension associated with 
malignant diseases in adult patients.
Pathological insights 
Pulmonary hypertension (PH) is defined as an increase 
in mean pulmonary artery pressure ≥ 25 mm Hg at rest, me-
asured by right heart catheterization. Based on clinical and 
hemodynamic characteristics, pulmonary hypertension can be 
classified into five groups including pulmonary arterial hyper-
tension (PAH), pulmonary veno-occlusive disease (PVOD) and 
drugs and toxins-related (Group1), left heart disease associated 
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Table I. pCR rate within the lymph nodes after preoperative chemotherapy








pulmonary hypertension (Group 2), lung disease associated 
pulmonary hypertension (Group 3), thromboembolic and va-
scular obstruction pulmonary hypertension (Group 4) and 
pulmonary hypertension due to unclear and/or multifactorial 
mechanisms such as pulmonary tumor thrombotic micro-
angiopathy (Group 5) [9]. Interestingly, pathological studies 
of primary pulmonary arterial hypertension showed altera-
tions in the cellular regulatory mechanisms controlling the 
growth and proliferation of pulmonary vascular endothelial 
cells and smooth muscles with subsequent abnormal proli-
feration, excessive angiogenesis and resistance to apoptosis 
which are the hallmarks of malignant diseases pathogenesis 
[10–12]. Malignant diseases can lead to elevated pulmonary 
artery pressure through different mechanisms, either directly 
by structural obstruction of pulmonary vessels or indirectly 
through hypercoagulable state or treatment toxicity culmi-
nating in high pulmonary vascular resistance. The incidence 
of pulmonary hypertension can be underestimated due to 
the shared presentation with more common complications 
in cancer patients such as heart failure and pulmonary dise-
ases. The most common causes of pulmonary hypertension 
in patients with neoplasia are related to pulmonary vascular 
narrowing or obstruction (chronic thromboembolic pulmonary 
hypertension, CTEPH, and tumor emboli) (Group 4) followed 
by pulmonary arterial hypertension and pulmonary veno-
-occlusive disease due to treatment toxicity (Group 1) and less 
common causes include intravascular tumors and malignant 
extrinsic compression (Group 4). 
Thromboemboli
Malignant diseases are a well-known risk factor for ve-
nous thromboembolic events (VTE) with 4.1 folds increased 
risk especially with cancers of pancreas, lung, stomach and 
primary of unknown origin. Cancer treatment can enhance 
the risk up to 6.5 folds [13]. Thrombosis in cancer is possibly 
triggered by the interaction of malignant cells with mono-
cytes or macrophages leading to endothelial dysfunction 
and activation of platelets and coagulation factors X and XII. 
Moreover, tissue factor and other procoagulants can be 
produced by malignant cells. All these prothrombotic factors 
end with activation of thrombin to produce fibrin binding 
clot [14]. Thromboemboli can obstruct major pulmonary 
arteries non-homogenously and persist despite antico-
agulation ensuing pulmonary vascular remodelling and 
ultimate chronic thromboembolic pulmonary hypertension 
(CTEPH) [15]. The primary cause of CTEPH, in general, is 
venous thromboembolic events with a history of pulmo-
nary embolism reported in 74.8% of patients and deep 
venous thrombosis in 56.1%. Malignancy is established as 
a risk factor for CTEPH with a history of cancer was found 
in about 12% of patients [16, 17]. A retrospective cohort of 
687 patients showed that the odds ratio of CTEPH increased 
in patients with a history of cancer (OR 3.76, CI 1.47–10.43). 
Longtime interval to diagnose CTEPH was reported (up to 
5–10 years) in survivors of cancer. Tumours of the breast, GIT, 
melanoma, prostate and seminoma are the most frequently 
associated with CTEPH [17]. Patients with CTEPH have poor 
prognosis in the presence of cancer even in patients eligible 
for surgical treatment with pulmonary endarterectomy [18]. 
Tumor emboli
Tumor emboli are one type of non-thrombotic pulmo-
nary emboli which separate from the primary tumour mass 
and reaching the pulmonary vasculature through venous 
circulation. These emboli are not a part of metastasis process 
as they remain intraluminal with no invasion of vascular wall 
tissue. Tumor emboli were found in 2.4–26% of autopsies 
of solid malignancy patients [19]. The size of the emboli is 
varying from small (microscopic), which is the most com-
mon and associated mainly with cancers of the stomach, 
liver, pancreas and choriocarcinoma; to the infrequent large 
(macroscopic) emboli that reported with liver, breast and 
renal cancers [20]. Clinical consequences depend on the 
extent of pulmonary vascular bed affected by a persistent 
mechanical obstruction and secondary reaction to the non-
-resolving emboli. Patients either remain asymptomatic 
especially with microscopic emboli or develop subacute 
dyspnea, cyanosis and features of right ventricular overload 
due to raised pulmonary artery pressure [21]. The differen-
tial diagnosis of pulmonary hypertension in patients with 
malignancy must include tumour emboli as a potential 
aetiology since the clinical spectrum are identical to the 
most common thrombotic emboli. However, identification 
of tumour emboli is challenging, and diagnosis is probably 
made post-mortem since imaging modalities are unable to 
specifically differentiate these emboli from other causes of 
pulmonary hypertension. Prognosis is poor and no specific 
treatment apart from palliative measures and management 
of a primary tumour [20, 22]. 
Pulmonary tumour thrombotic microangiopathy
Pulmonary Tumour Thrombotic Microangiopathy 
(PTTM) is a particular presentation of microscopic tumour 
emboli that triggered diffuse reaction to the deposition 
of migrating malignant cells by inducing fibrocellular and 
fibromuscular proliferation in the walls of small pulmonary 
arteries and arterioles with the formation of microthrombi 
leading to diffuse vascular obliterations with subsequent 
pulmonary hypertension [23]. PTTM is rare with an inciden-
ce rate 1.4–3.3% in autopsy series and most cases (> 90%) 
associated with adenocarcinoma, most frequently gastric 
adenocarcinoma and less commonly lung, oesophagus, 
liver, colon, common bile duct, pancreas, breast, urinary 
bladder, prostate and parotid gland carcinomas [24, 25]. 
It is commonly detected in advanced stages of cancer and 
can affect patients in younger age (< 40 years). It is possible 
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for patients to present with clinical features of PTTM prior 
to the discovery of underlying malignancy. Patients are 
usually presented with dyspnea and cough progressing 
to pulmonary hypertension, and right heart failure with 
rapid deterioration and fatal outcome are the common 
consequence [26]. Most cases are discovered at biopsy sin-
ce there are no radiological features specific to PTTM, CT 
scan may be normal or shows dilated pulmonary arteries, 
wedge-shaped opacities peripherally, thickened interlo-
bular septa or Tree-in-bud sign (centrilobular nodules with 
linear opacities) [27]. Perfusion studies may demonstrate 
defects and pathological studies with cytology and biopsy 
percutaneously or surgically may help in some cases [28]. 
Apart from supportive treatment and chemotherapy for the 
underlying malignancy, no specific treatments are available 
to withhold this fatal complication with most patients are 
dying shortly after diagnosis [29]. It is important to consider 
PTTM as a cause of unexplained dyspnea with malignancy 
and on the other side to look for undiagnosed cancer in 
patients presenting with pulmonary hypertension possibly 
due to PTTM.
Pulmonary artery sarcoma
A rare type of an intravascular tumour originating from 
the intimal cells of the pulmonary artery with different hi-
stopathological types such as undifferentiated, leiomyosar-
coma, spindle cell sarcoma and rhabdomyosarcoma [30]. 
Involvement of pulmonary artery is usually bilateral but 
can be unilateral. Patients often present with clinical and 
radiological features mimicking pulmonary thromboem-
bolic disease. Misdiagnosis of pulmonary artery sarcoma 
for pulmonary chronic thromboembolic hypertension is 
possible with delayed diagnosis resulting in increased mor-
tality  [31]. The prognosis is poor, but overall survival can 
improve with complete surgical resection with a potential 
role for post-surgical chemo and radiotherapy. However, 
curative surgery is not possible in all patients, and sympto-
matic benefit can be obtained with other surgical options 
including pulmonary artery endarterectomy [32]. 
Malignant compression of pulmonary artery
Extrinsic compression of pulmonary arteries by a mali-
gnant mass can result in acquired pulmonary artery stenosis 
with clinical features of pulmonary hypertension and right 
heart pressure overload. Malignant pulmonary artery ste-
nosis is caused by primary or secondary thoracic cancers 
especially lung cancer, lymphoma, mediastinal tumours 
and secondary metastases. Malignant compression can in-
volve one or both major pulmonary arteries. The incidence 
is not common with few reported cases with a history of 
malignancy, but it is possible to be the first presentation of 
cancer. In addition to treatment of underlying malignan-
cy, palliative endovascular stenting can help in promoting 
symptomatic improvement through relief of pulmonary 
artery stenosis [33–36]. 
Treatment-related toxicity
Cardiovascular toxicity is a major complication of speci-
fic cancer treatments affecting the quality of life and progno-
sis. Cardiovascular risk factors, genetic and environmental 
elements and concomitant use of therapies with negative 
impact on the CV system can augment the risk of toxicity 
related to cancer treatment [37]. The damage can be perma-
nent related to cell loss (irreversible damage) or temporary 
caused by alterations in cellular proteins and mitochondrial 
structure (reversible dysfunction) [38]. Pulmonary hyperten-
sion is a rare but serious side effect of chemotherapy, and it 
is known to be associated with certain chemotherapeutic 
agents including dasatinib, cyclophosphamide, bortezomib, 
carfilzomib and interferon-a [39]. Attention is increasingly 
focused on the prevention, early detection and treatment 
of CV complications in patients with malignancy. Recent 
recommendations from the European society of cardio-
logy emphasized the importance of monitoring patients 
receiving drugs known for risk of inducing pulmonary hy-
pertension. The surveillance aims for early detection by 
using clinical assessment and echocardiography before 
starting treatment as a baseline and at regular intervals 
thereafter [40]. 
Dasatinib
A potent tyrosine kinase inhibitor used in the treatment of 
chronic myelogenous leukaemia by blocking BCR/ABL kinase 
1 and in addition inhibiting the SRC family kinases, c-Kit and 
platelet-derived growth factor-receptor (PDGFR). Dasatinib is 
associated with a range of significant non-haematological side 
effects including pleural and pericardial effusion and arrhyth-
mias. Pulmonary artery hypertension is reported in patients 
using dasatinib but not with other TKI excluding the class-ef-
fect possibility. However, the underlying pathophysiological 
mechanism is unknown, and some suggest a secondary immu-
ne reaction or possibly uncontrolled proliferation of vascular 
endothelium and smooth muscles caused by inhibition of the 
regulatory SCR kinase [41]. The incidence of PH in patients re-
ceiving dasatinib varied from (0.45% to 12%) [42–44] and it can 
be detected early up to 2 months or late about 48 months after 
initiation of dasatinib [42, 43]. Follow-up of patients showed 
reversibility of PH with discontinuation or reducing the dose 
of dasatinib. However, complete recovery may not be possible 
in every affected patient after all [44]. 
Alkylating agents
Development of PVO disease which is an uncommon 
cause of PH has been reported in 37 patients with different 
solid organ and haematological malignancies. Prior use of 
alkylating agents has been identified as the main risk factor 
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in 83.8% of patients. The implicated alkylating agents with 
later development of PVO disease are cyclophosphamide 
which is the most common (43.2%), mitomycin (24.3%) and 
cisplatin (21.6%). A study of animal models demonstrated a 
direct relationship between exposure to alkylating agents 
especially cyclophosphamide and development of pulmo-
nary venous remodelling leading to PVOD and PH. The study 
also showed a beneficial role for the cytoprotective agents 
mesna and amifostine to protect pulmonary vasculature 
from the harmful effects of chemotherapy [45].
In the French registry, patients with squamous anal 
cancer receiving mitomycin had a higher incidence of PVOD 
than in the general population with rapid progression and 
poor outcomes. An experimental study on rats confirmed 
the role of mitomycin in inducing vascular changes iden-
tical to that of PVOD in humans. The study also showed 
a protective role for amifostine that helped in improving 
outcomes [46]. 
Proteasome inhibitors
The ubiquitin-proteasome pathway maintains cellular 
integrity through degradation of proteins involved in a wide 
range of processes such as apoptosis, DNA repair and anti-
gen presentation. Dysfunctions in the ubiquitin-proteasome 
pathway can lead to unbalanced protein synthesis and de-
velopment of various diseases including malignant diseases 
[47]. Bortezomib, the first generation of proteasome inhibitors 
used for the treatment of multiple myeloma and mantle cell 
lymphoma, has an infrequent incidence of cardiovascular 
side effects with PH rarely reported [48, 49]. The manufacturer 
advises stopping bortezomib temporarily in case of diagno-
sing PH and referring patients for specialist advice. On the 
contrary, research on animals showed a potential benefit of 
bortezomib in reversing vascular smooth muscle proliferation 
and endothelial dysfunction in patients with PAH [50, 51]. 
Carfilzomib, second generation and more potent prote-
asome inhibitor effectively used in the treatment of relap-
sing and refractory multiple myeloma, has been associated 
with significant cardiac and vascular toxicities including 
pulmonary hypertension. Phase II studies reported an inci-
dence reaching 2% of PH in patients receiving carfilzomib 
[52]. The underlying mechanism for vascular adverse effects 
is not defined yet but could be related to endothelial injury 
causing impaired vascular relaxation and vasospasm [53]. 
Reports indicate that PH occurred infrequently especially 
in patients having cardiovascular risk factors such as atrial 
fibrillation and arterial hypertension or patients with history 
of cardiovascular diseases which necessitate close clinical 
monitoring of those patients in case they develop dyspnea 
or other signs and symptoms suggestive of PH [54, 55]. 
Pulmonary hypertension usually occurs early in the course 
of carfilzomib treatment and it is reversible with discontinu-
ation of treatment and supportive treatment [53]. 
Interferon a
An immunoregulatory cytokine with antineoplastic fe-
atures used in the treatment of chronic myeloid leukaemia, 
hairy cell leukaemia, lymphoma, renal cell cancer, melanoma 
and Kaposi sarcoma [56]. Interferon α has been reported for 
a rare but significant risk of pulmonary hypertension [57]. 
Interferon has been linked to an increased level of Endothe-
lin-1 which is an important modulator in the pathogenesis of 
PH [58]. Pulmonary hypertension diagnosis may be delayed 
long, up to 3 years, after initiation of interferon treatment. 
Discontinuation of interferon is helpful to halt the progres-
sion of PH, but in some patients, use of vasodilator therapies 
was needed [59]. 
Bleomycin
A cytotoxic antibiotic used mainly in the treatment of 
Hodgkin lymphoma and germ-cell tumours. Bleomycin is 
well known for pulmonary toxicity mainly presents as inter-
stitial pneumonitis that can progress to pulmonary fibrosis 
leading to a high mortality rate 3% [60]. The mechanism 
of pulmonary toxicity is thought to be related to sever in-
flammatory reaction releasing cytokines and free radicals 
leading to endothelial injury and subsequent fibrosis [61]. 
Pulmonary hypertension rarely develops in patients re-
ceiving bleomycin with histological evidence of capillary 
endothelial oedema and pulmonary veno-occlusive disease 
has been demonstrated [62]. Bleomycin has been suggested 
as the main factor in causing pulmonary veno-occlusive 
disease in a reported series of patients [63, 64]. Bleomycin 
has long track of being used in experimental studies to 
induce idiopathic pulmonary fibrosis and pulmonary hy-
pertension [65–68]. Management usually directed toward 
supportive treatment, steroids and azathioprine with a po-
ssible role for imatinib and bosentan [69–71]. 
Gemcitabine
A cytosine arabinoside analogue used for the treatment 
of different solid organ tumours either as a single agent 
for metastatic pancreatic cancer or in combination with 
other agents for the treatment of lung, breast, and bladder 
cancers. Gemcitabine is known for myelosuppression and 
pulmonary side effects but two cases reported for the de-
velopment of PH after receiving gemcitabine. Clinical and 
radiological features indicated PVOD as the cause of pa-
tients’ symptoms that developed secondary to gemcitabine 
exposure. It is possible that discontinuation of gemcitabine 
may help in reversing the progression of PVOD and stabili-
zation affected patients [72, 73]. 
Radiotherapy
There is an increased incidence of cardiovascular com-
plications in patients who received radiotherapy, mainly 
those with Hodgkin’s lymphoma, breast cancer and lung 
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cancer. However, with advances in radiotherapy protocols 
and technology, the incidence has been dropped significan-
tly. Pulmonary hypertension is a rare complication of radio-
therapy. Pulmonary hypertension has been suggested to be 
secondary to inflammatory vascular injury provoked by chest 
radiotherapy leading to arterial remodelling and lumen obli-
teration [74] that could be similar to vasculopathy triggered 
by head and neck irradiation that evolve into stenosis of major 
supra-aortic arteries [75]. Mediastinal fibrosis also implicated 
as a possible cause of external compression of pulmonary 
arteries [76]. Sporadic cases of pulmonary artery stenosis 
have been reported several years after receiving radiotherapy 
presenting with dyspnea and features of raised pulmonary 
pressure similar to other more common presentations such as 
chronic thromboembolic disease [76–78]. Pulmonary artery 
stenosis needs to be considered in the differential diagnosis 
of patients with a history of irradiation and dyspnea as the 
management can be successful with rapid improvement of 
pulmonary artery pressure using endovascular stenting the-
rapy [77]. Radiotherapy was rarely pointed as a possible cause 
of pulmonary veno-occlusive disease leading to pulmonary 
hypertension [79]. 
Hemopoietic stem cell transplantation
Pulmonary hypertension is one of dreadful complica-
tions that can arise following HSCT both in adult and pe-
diatric populations. Although the incidence is rare but it is 
associated with a considerable morbidity and high mortality 
(up to 55% of affected patients). Both pulmonary arterial and 
venous circulations can be involved and patients usually 
presented early in the first year after transplantation [80]. 
The underlying mechanism is not clearly defined but the evi-
dence from pathological studies showed an inflammatory 
process resulting in intimal thickening and vascular wall hy-
pertrophy ending with lumen narrowing and raised vascular 
resistance [81]. However, it is possible that pre-transplant 
chemotherapeutic regimes and radiotherapy may have a 
contributing role in pulmonary vascular damage [82]. Most 
reported patients have pulmonary arterial hypertension, 
about 70% of transplanted patients with pulmonary hy-
pertension, mainly involving the arteriolar tree  [80]. Pul-
monary veno-occlusive disease is a less common cause 
of pulmonary hypertension after HSCT with endothelial 
injury, intimal fibrosis and lumen obliteration of venules 
and small veins result in post-capillary hypertension [83]. 
Clinical presentation is non-specific similar to other causes 
of PH and diagnosis can be difficult with lung biopsy may 
be needed to prove the diagnosis [84]. 
Conclusion
Cardiovascular diseases are the main health challenge in 
patients with or surviving malignancy. Although pulmonary 
hypertension is rare, it carries significant morbidity and 
mortality and needs to be considered in the differential 
diagnosis of unexplained cardiopulmonary symptoms. Also, 
monitoring is necessary for patients receiving treatment 
with the known risk of pulmonary hypertension.
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